Iclaprim

N/A

Report date: 2022/07/04 19:38:02
NMEQIDP

Base Information

Drug NameIclaprim
Drug Alias Name艾拉普林Iclaprime埃拉普林IclaprimIclaprimum +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydrofolate reductase inhibitors
TargetsDihydrofolate reductase
Therapy Area/IndicationsAcute bacterial skin and skin structure infectionsPneumonia, Ventilator-AssociatedHealthcare-Associated Pneumonia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[19] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMotif Bio PlcArpida Ag
Active IndicationsN/A
Inactive IndicationsAcute bacterial skin and skin structure infectionsPneumonia, Ventilator-AssociatedHealthcare-Associated Pneumonia +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG